Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | anaplastic thyroid carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Guideline | Actionable | Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for patients with advanced or metastatic thyroid gland anaplastic carcinoma harboring BRAF V600E (PMID: 31549998, PMID: 35491008; ESMO.org). | 31549998 detail... 35491008 |
BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 61% (20/33; 3 complete responses, 17 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E, with 12-month duration of response rate of 50%, a median progression-free survival and overall survival of 6.7 and 14.5 months, respectively (PMID: 35026411; NCT02034110). | 35026411 detail... detail... detail... |
BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975). | 27697975 |
BRAF V600E | anaplastic thyroid carcinoma | sensitive | Dabrafenib + Trametinib | Guideline | Actionable | Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for metastatic thyroid gland anaplastic carcinoma patients harboring BRAF V600E (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
(27697975) | Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. | Full reference... |
NCCN.org | Full reference... | |
ESMO Clinical Practice Guidelines | Full reference... | |
Full reference... | ||
Mekinist (trametinib) FDA Drug Label | Full reference... | |
Tafinlar (dabrafenib) FDA Drug Label | Full reference... | |
(35491008) | ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. | Full reference... |
(31549998) | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. | Full reference... |
(35026411) | Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. | Full reference... |